Carlos Rodriguez-Galindo, M.D.

Committee Member

Dr. Carlos Rodriguez-Galindo’s clinical research has focused on the development of innovative therapies for pediatric solid tumors such as retinoblastoma, sarcomas, and rare cancers. He is the principal investigator of multi-institutional trials on childhood nasopharyngeal carcinoma, adrenocortical carcinoma, Langerhans cell histiocytosis, and recurrent germ cell tumors, and he has been the principal investigator of several phase I studies and a phase III study for patients with retinoblastoma.

Dr. Rodriguez-Galindo has been involved in the development of pediatric oncology programs in countries with limited resources. He has assisted in the development of pediatric oncology centers in Mexico, Central and South America, Africa, and Southeast Asia. He is the director of the new Global Health Initiative in Pediatric Hematology and Oncology of the Dana-Farber/Children’s Hospital Cancer Center. The program integrates program building, research, and education as well as new models for intervention to improve outcome for those children with cancer and blood disorders in countries with limited resources. Current research lines within the program include new models of pediatric cancer care delivery in resource-limited settings, application of decision analysis methods in resource allocation, development of a resource-level index in pediatric oncology, and molecular epidemiology of childhood cancer.